1. Home
  2. NKLR vs ANNX Comparison

NKLR vs ANNX Comparison

Compare NKLR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NKLR

Terra Innovatum Global N.V. Ordinary shares

N/A

Current Price

$5.97

Market Cap

313.5M

Sector

Industrials

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$6.14

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKLR
ANNX
Founded
2018
2011
Country
Italy
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.5M
334.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NKLR
ANNX
Price
$5.97
$6.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$17.50
$16.50
AVG Volume (30 Days)
902.6K
2.9M
Earning Date
05-14-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.73
$1.29
52 Week High
$21.91
$6.83

Technical Indicators

Market Signals
Indicator
NKLR
ANNX
Relative Strength Index (RSI) N/A 63.79
Support Level N/A $5.12
Resistance Level N/A $6.83
Average True Range (ATR) 0.00 0.45
MACD 0.00 0.06
Stochastic Oscillator 0.00 68.71

Price Performance

Historical Comparison
NKLR
ANNX

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: